LNAI - Enochian Biosciences Inc

0.3262
-0.014   -4.231%

Share volume: 1,276,046
Last Updated: 04-21-2026
Pharmaceutical Products/Pharmaceutical Preparations: 3.15%

PREVIOUS CLOSE
CHG
CHG%
$0.34
-0.01
-0.04%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
58%
Profitability 58%
Dept financing 50%
Liquidity 1%
Performance 75%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
-6.51%
1 Month
-20.54%
3 Months
-64.47%
6 Months
-67.38%
1 Year
-6.32%
2 Year
-84.83%
Key data
Stock price
$0.33
P/E Ratio 
0.00
DAY RANGE
$0.31 - $0.34
EPS 
$0.01
52 WEEK RANGE
$0.12 - $1.66
52 WEEK CHANGE
-$13.15
MARKET CAP 
20.660 M
YIELD 
N/A
SHARES OUTSTANDING 
24.187 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
N/A
BETA 
2.35
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$5,527,557
AVERAGE 30 VOLUME 
$22,572,983
Company detail
CEO: Mark R. Dybul
Region: US
Website: enochianbio.com
Employees: 20
IPO year: 2015
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

Enochian Biosciences, Inc. engages in the research and development of pharmaceutical and biological products for the human treatment of human immunodeficiency virus (HIV), hepatitis B virus (HBV), influenza and coronavirus infections, and cancer. The company's lead candidate includes ENOB-HV-01 for autologous HIV curative treatment.

Recent news